Clinical Trial Update: Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing empagliflozin to placebo for the rate of arrhythmic events in patients with heart failure and diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Heart Failure

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Rambam Health Care Campus | Conditions: Heart Failure, Diabetes Mellitus | Phase 4 | Status: UNKNOWN